The global Non-alcoholic Steatohepatitis Biomarkers market size is expected to be worth around US$ XX billion by 2030, according to a new report by Vision Research Reports.
The global Non-alcoholic Steatohepatitis Biomarkers market size was valued at US$ 300.04 million in 2020 and is anticipated to grow at a CAGR of 40.1 % during forecast period 2021 to 2030.
The growing prevalence of chronic liver conditions is expected to upsurge demand for noninvasive diagnostic tools, fueling the demand for these products in the coming years.
The incidence of NASH (Non-alcoholic Steatohepatitis) has progressed over time, and it usually leads to liver failure. Twenty percent of patients suffering from this disease are prone to cirrhosis-a condition wherein healthy tissues are replaced with scar tissues-and 10% succumb to death. According to estimates by the United States Census Bureau in 2009, people older than 65 represented around 13% of the total population in the U.S., and this is expected to grow to an estimated 20% by 2030.
Increasing demand for noninvasive diagnostic tools coupled with rising levels of patient awareness is expected to augment the development of NASH biomarkers over the forecast period. The high cost of liver biopsy, invasiveness, and limited acceptance by patients are the factors responsible for the lower adoption of invasive techniques for disease diagnosis. Identification of NASH is difficult and, currently, liver biopsy is a gold standard for identification of the difference between Nonalcoholic Fatty Liver Disease (NAFLD) and NASH. However, the disadvantages associated with its usages, such as invasiveness and high cost, resulted in shifting of preference toward noninvasive biomarkers. This is anticipated to propel the market growth over the forecast period.
Imaging techniques such as computed tomography, magnetic resonance imaging, and ultrasound scanning can accurately diagnose NAFLD. However, these techniques proved inefficient in the detection of liver fibrosis or NASH. These factors are anticipated to further boost demand for noninvasive diagnostic tools, such as serum biomarkers, for disease diagnosis in the coming years, eventually driving the NASH biomarkers market growth.
Serum biomarkers held a dominant share as of 2016. These are the most commonly used diagnostic tools for the detection of NASH. Also, the introduction of emerging products, such as leptin, ghrelin & tumor necrosis factor-alpha, free fatty acids, apolipoprotein B, apolipoprotein A1, and adiponectin, that can offer valuable services complementary to the traditional ones is predicted to propel the segment growth.
Also, serum biomarkers are anticipated to dominate the types segment, owing to its associated benefits such as the ability to distinguish simple steatosis from NASH and efficient outcomes. These benefits reduce the need for liver biopsy, which is an added advantage compared to other segments.
Serum biomarkers also found applications in the diagnosis of prostate, ovarian, lung, colorectal, and breast-related disorders. Expanding applications of this segment are considered as major factors responsible for its largest revenue share. The key players responsible for offering these products are GE Healthcare; EUSA Pharma; Eli Lilly & Co.; CytoCore, Inc.; Bruker Daltonics, Inc.; Biomarker Technologies, LLC; BioCurex, Inc.; Agilent Technologies; and Abbott Diagnostics.
However, hepatic fibrosis biomarkers are anticipated to witness the fastest growth during the forecast period, owing to their high accuracy and efficacy. These biomarkers act as an affordable and attractive alternative for the diagnosis of diseases for both patients and physicians.
The pharmaceutical industry and Contract Research Organizations (CROs) held a dominant share as of 2016. This segment is expected to exhibit a lucrative growth rate in the coming years. Rising demand for noninvasive NASH diagnostic &monitoring tools in the ongoing clinical trials by CROs and pharmaceutical manufacturers can be attributed to its strong growth.
Many companies are involved in research about NASH therapeutics. However, certain factors such as complex pathophysiology, unknown etiology, and the high cost of treatment are anticipated to restrain the revenue growth of this end-user segment during the forecast period.
During clinical trials, a noninvasive technique for routine monitoring of drug therapy is preferred, which is expected to boost the adoption of biomarker tests in NASH diagnostics. After drug launch, the use of biomarkers in hospitals and diagnostic laboratories for assessing prognosis is anticipated to increase. Hence, by the end of the forecast period, it is anticipated that the market for hospitals and diagnostic laboratories will witness higher growth owing to rising initiatives about the development of novel drugs for NASH treatment.
Products that are currently in the pipeline will be launched and established by 2025, which is expected to boost the adoption of biomarker tests. Increasing demand for companion diagnostic tests and the ability of biomarkers to distinguish simple steatosis from NASH is expected to fuel the segment growth in the coming years.
The growth of the Non-alcoholic steatohepatitis biomarkers market in North America can be attributed to various factors such as favorable government initiatives and rising prevalence of infectious diseases, cardiovascular diseases, & cancer. Funding for R&D of biomarkers is high, which supports drug development activities, thereby fueling industry growth.
Moreover, government regulations support research activities for the development of novel molecules in North America, which is anticipated to surge industry growth. Also, the local presence of key players in this region can be attributed to strong regional growth. The NASH biomarkers industry in this region is anticipated to witness lucrative CAGR in the coming years.
GENFIT; Gilead; AstraZeneca; Novartis AG; Bristol-Myers Squibb; Allergan Novo Nordisk A/S; Boehringer Ingelheim GmbH; and Pfizer, Inc.
Hepatic fibrosis biomarkers
Oxidative stress biomarkers
Pharma & CRO Industry
Academic Research Institutes
The Middle East and Africa
The Non-alcoholic Steatohepatitis Biomarkers market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Non-alcoholic Steatohepatitis Biomarkers market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Non-alcoholic Steatohepatitis Biomarkers market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-alcoholic Steatohepatitis Biomarkers market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Non-alcoholic Steatohepatitis Biomarkers market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Non-alcoholic Steatohepatitis Biomarkers capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Non-alcoholic Steatohepatitis Biomarkers by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Non-alcoholic Steatohepatitis Biomarkers market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Non-alcoholic Steatohepatitis Biomarkers market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Non-alcoholic Steatohepatitis Biomarkers market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Non-alcoholic Steatohepatitis Biomarkers industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Non-alcoholic Steatohepatitis Biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Non-alcoholic Steatohepatitis Biomarkers market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Non-alcoholic Steatohepatitis Biomarkers market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Non-alcoholic Steatohepatitis Biomarkers market. These factors have benefited the growth of the global market for Non-alcoholic Steatohepatitis Biomarkers. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Non-alcoholic Steatohepatitis Biomarkers. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Non-alcoholic Steatohepatitis Biomarkers are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Trauma Care Centers Market (By Facility Type: In-house, Standalone; By Trauma Type: Falls, Traffic-related Injuries; By Service Type) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Monkeypox Vaccine And Treatment Market (By Product: Vaccine, Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Hyaluronic Acid Market (By Application: Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
AI in Oncology Market (By Treatment: Chemotherapy, Radiotherapy, Immunotherapy, Targeted Therapy, Gene Therapy; By Cancer Type; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Paracetamol IV Market (By Application: Surgical, Non-surgical; By Indication: Pyrexia, Pain; By End-use: Hospitals, Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...